Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system | Zendy

Wei Liu | Zendy; Jialong Yan | Zendy; Weinan Pan | Zendy; Mengjie Tang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system

Author(s) -

Wei Liu,

Jialong Yan,

Weinan Pan,

Mengjie Tang

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.07

Subject(s) - apelin , medicine , angiogenesis , vasodilation , cardiology , vasculogenesis , heart failure , angiotensin ii , receptor , progenitor cell , biology , stem cell , genetics

Apelin and Elabela (ELA) are endogenous ligands of angiotensin domain type 1 receptor-associated proteins (APJ). Apelin/ELA-APJ signal is widely distributed in the cardiovascular system of fetuse and adult. The signal is involved in the development of the fetal heart and blood vessels and regulating vascular tension in adults. This review described the effects of apelin/ELA-APJ on fetal (vasculogenesis and angiogenesis) and adult cardiovascular function [vascular smooth muscle cell (VSMC) proliferation, vasodilation, positive myodynamia], and relative diseases [eclampsia, hypertension, pulmonary hypertension, heart failure (HF), myocardial infarction (MI), atherosclerosis, etc.] in detail. The pathways of apelin/ELA-APJ regulating cardiovascular function and cardiovascular-related diseases are summarized. The drugs developed based on apelin and ELA suggests APJ is a prospective strategy for cardiovascular disease therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research